Olanzapine: An atypical antipsychotic for schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 2, 2000, Pages 305-323

  Lund, Brian C ^a   Perry, Paul J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Adverse effects; Mania; Olanzapine; Parkinson 's disease; Pharmacokinetics; Pharmacology; Schizophrenia; Scliizoaffective disorder

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; PIRENZEPINE;

CLINICAL TRIAL; ECONOMICS; HUMAN; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; HUMANS; PIRENZEPINE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0033766204     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.2.305     Document Type: Article

References (104)

1. TSUANG MT, FAKONE S: Schizophrenia. In: The Medical Basis of Psychiatry. Winokur G, Clayton PJ (Eds.), WB Saunders Co., Philadelphia, USA (199-0:87-114.
2. Zyprexa package insert. Eli Lilly & Co. (November 199S).
3. BYMASTER FP, CALLIGARO DO, FALCONE FJ et al.: Radioreceptor binding profile of the atypical antipsychotic olanzapinc. Neuropsychopharmacology (1996) 14(2):87-96.
4. KICHELSON E: Receptor pharmacology of neuroleptics: relation to clinical effects. J. Clin. Psychiatry (1999) 60(Suppl. 10):5-14.
5. PERRY PJ, SANGER T. BEASLEY C: Olanzapine concentrations and clinical response in acutely ill schizophrenic patients. J. Clin. Psycbopbarmacol. (1997) 17(6):472-477. Provides a therapeutic drug monitoring strategy for olanzapine.
6. KASSAHUN K, MATTIUZ E. NYHART E et al.: Disposition and biotransformation of the antipsychotic agent olanzapinc in humans. Dntg Melab. Dispos. (1997) 25(1):81-93.
7. RING ISJ, CATLOW J, LINDSAY TJ et al.: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidativc metabolites of the antipsychotic agent olanzapinc. J Pbanucol. Exp. Tber. (1996) 276(2):658-666.
8. LUCAS RA, GILFILLAN DJ, BERGSTROM RF: A pharmacokinctic interaction between carbaniazepine and olanzapinc: observations on possible mechanism. Enr.J. Clin. Pbarmacol. (1998) 54(8):639-643.
9. MICHALETS EL: Update: clinically significant cytochrome P-450 drug interactions. Pbannacolherapy (1998) 18(1);84-112. A thorough review of clinically relevant drug interactions.
10. OVERALL JE, GORHAM DR: Brief Psychiatric Rating Scale. In: ECDEU Assessment Manual Guy W (Ed.), US Department of Health, Education and Welfare, Bethesda, USA (1976):157-169.
11. KAY SR, FISZBEIN A, OPLEK LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Scbtzuphr. Bull. (1987) 13(2):261-276.
12. ANDREASEN KC: Negative symptoms in schizophrenia. Arch. Geu. Psychiatry (1982) 39C7)784-788.
13. GUY W: Clinical global impressions. In: ECDEV Assessment Manual. Guy W (Ed.), US Department of Health. Education and Welfare, liethesda, USA (1976):217-222.
14. MONTGOMERY SA, ASIiERG M: A new depression scale designed to be sensitive to change. Br. J. Psychiatry (1979) 134(4):382-389.
15. YOUNG RC. BIGGS JT, ZIEGLER VE. MEYER DA: A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry(1978) 133(5):429-B5.
16. GUY W: Clinical global impressions. In: ECDEU assessment manual. Guy W (Ed.), US Department of Health, Education and Welfare. Bethesda, USA (1976):534-537.
17. SIMPSON GM, ANGUS JVC'S: A rating scale for extrapyramidal side effects. Ada Psycbiatr. Scancl. (1970)212:511-519.
18. BARNES TRE: A rating scale for drug-induced akathisia. Br. J. Psycbiatry(1989) 154(5):672-676.
19. BEASLEY CM Jr., SANGEK T, SATTERLEE W, TOLLEFSON G, TRAN P, HAMILTON S: Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapinc trial. Pychopharmacology (1996) 124(1-2):159-167.
20. SHEITMAN BB, LINDGREN JC, EARLY J, SVED M: High-dose olanzapine for treatment-refractory schizophrenia. Am. J. Psychiatry. (1997) 154(11):1626.
21. MOUNTJOY CQ, BALDACCHINO AM, STUBBS JH: British experience with high-dose olanzapinc for treatment-refractory schizophrenia. Am.J. Psychiatry (1999) 156(1):158-159.
22. REICH J: Use of high-dose olanzapine in refractory psychosis. Am.J. Psychiatry(.1999) 156(4):661.
23. BEASLEY CM, JR., TOLLEFSON G, TRAN P, SATTERLEE W, SANGER T HAMILTON S: Olanzapinc versus placebo and halopcridol. Acute phase results of the North American double-blind olanzapinc trial. Neuropsychopbarmacology (1996) 14(2):111-123. The principal efficacy study for olanzapine.
24. BEASLEY CM Jr, HAMILTON SH, CKAWFORD AM et al.: Olanzapinc versus halopcridol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsychophamacol. (1999) 7(2):125-137.
25. TOLLEFSON G, BEASLEY CM Jr., TRAN P et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psycbiatry (1997) 154(4):457-465.
26. TRAN PV, HAMILTON SH, KUNTZ AJ et al.: Double-blind comparison of olanzapinc versus risperidonc in the treatment of schizophrenia and other psychotic disorders. J Clin. Psychopharmacol. (1997) 17(5);407-418. A comparison of olanzapine with the atypical antipsychotic risperidone.
27. KANEJ, HONIGFELD G, SINGERJ, MELTZER H: Clozapinc for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1988) 45(9):789-796. A landmark study of the treatment of refractory schizophrenia.
28. COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS: Assessing the effects of atypical antipsychotics on negative symptoms..J. Clin, Phychiatry (1998) 59(Suppl. 12):28-34.
29. FLAUM M, ANDREASEN N: The reliability of distinguishing primary versus secondary negative symptoms. Compr. Psychiatry (1995) 36(6):421-427.
30. ALLAN ER, SISON CE, ALPERT M, CONNOLLY II, CRICHTON J: The relationship between negative symptoms of schizophrenia and cxtrapyramidal side effects with halopcridol and olanzapinc. ycbopbtmnacol. Bull. (1998) 34(l):71-74.
31. TOLLEFSON GD, SANGER TM: Negative symptoms: a path-analytic approach to a double-blind, placcboand halopcridol-controllcd clinical trial with olanzapine. Am.J. Psych iatiy 11997) 154(4):466-474. Provides a mathematical argument that olanzapine has a direct benefit on primary negative symptoms.
32. IDANPAAN-HEIKKILA J, ALHAVA E, OLKINUORA M. PALVA IP: Agranulocytosis during treatment with clozapine. Eur.J. Clin. Phannacol. (1977) 11(3):193-198.
33. HENDERSON DC, NASRALLAH RA, GOFF DC: Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response./ Clin. Psychiatry (.1998) 59(ll):5S5-588.
34. THOMAS SG, LABBATE LA: Management of treatment-resistant schizophrenia with olanzapine. Can.J. Psychiatry (1998) 43(2):195-196.
35. SANDERS RD, MOSSMAN D: An open trial of olanzapine in patients with treatment-refractory psychoses. J. lin. Psycbopbaniiacol. (1999) 19(l):62-66.
36. MARTIN J, GOMEZ JC, GARCIA-BERNARDO E et al.: Olanzapine in treatment-refractory schizophrenia: results of an open-label study./ Clin. Psychiatry (1997) 58(11):479-483.
37. CONLEY RR, TAMMINGA CA, BARTKO JJ et al.: Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J Psychiatry (1998) 155(7):914-920. A negative study of olanzapine in rigorously defined treatment refractory schizophrenia.
38. CONLEY RR, TAMMINGA CA, KELLY DL, RICHARDSON CM: Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol. Psychiatry (.1999) 46(l):73-77.
39. BREIER A, HAMILTON SH: Comparative efficacy of olanzapine and halopcridol for patients with treatment-resistant schizophrenia. Btol. Psychiatry (1999) 45(4):403-411.
40. MARDER SU: Newer antipsychotics in treatment-resistant schizophrenia, [iiol. Psychiatry (1999)45(4>:383-384.
41. GILBERT PL, HARRIS MJ, MCADAMS LA, JESTE DV: Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch. Ceil. I'sycbiatry (1995) 52(3):173-18S.
42. DELLVA MA. TRAN P, TOLLEFSON GD, WENTLEY AL, BEASLEY CM, JR.: Standard olanzapinc versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psycbiatr. Sen: (1997) 48(12):1571-1577.
43. TRAN PV. DELLVA MA. TOLLEFSON GD. WENTLEY AL, BEASLEY CM, JR.: Oral olanzapinc versus oral halopcridol in the maintenance treatment of schizophrenia and related psychoses. Br.J. I'sycbiatry (,\y)&) 172(6.1:499-505. Supports the efficacy of olanzapine in the maintenance treatment of schizophrenia.
44. TRAN PV, TOLLEFSON GD. SANGER TM. LU Y, BERG PH, BEASLEY CM, JR.: Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long-term therapy. Br.J.Psycbialrj'(.\y?)) 174(1): 15-22.
45. WEISLER RH, AHEARN EP, DAVIDSON JRT, WALLACE DC: Adjunctive use of olanzapinc in mood disorders: five case reports. Ann. Clin. Psychiatry (1997) 9(4):259-262.
46. MCELROY SL, FRYE M, DENICOFF K et al.: Olanzapine in treatment-resistant bipolar disorder. J Affect. Disonl. (1998)49(2):119-122.
47. KETTER TA, WINSBERG ME. DEGOLIA SG, DUNAI M. TÄTE DL, STRONG CM: Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. j Clin. Psychiatry-(1998) 59(2):83-83.
48. SHARMA V, PISTOR L: Treatment of bipolar mixed state with olanzapinc. J. Psychiatry Neurosci. (1999) 24(1):40-44.
49. ROTHSCHILD AJ, BATES KS, BOEHRINGER KL. SYED A: Olanzapine response in psychotic depression. J. Clin. Psychiatry (1999) 60(2):116-11l8.
50. ZARATE CA, NARENDRAN R, TOHEN M et til.: Clinical predictors of acute response with olanzapinc in psychotic mood disorders. J. Clin. Psychiatry (1998) 59(1):24-28.
51. TOHEN M, SANGER TM, MCELROY SL et al.: Olanzapinc versus placebo in the treatment of acute mania. Ain.J. Psychiatry (1999)) 156(5):702-709. Preliminary study of olanzapine in acute mania.
52. TOHEN M, ZARATE CA: Antipsychotic agents and bipolar disorder. J. Clin. Psychiatry (1998) 59(Suppl. 1):38-48.
53. CONSENSUS GUIDELINE PANEL: Selecting adjunctive medication for psychosis, agitation, and insomnia in manic, mixed, and hypomanic episodes. J Clin. Psychiatry (1996)57(SuppI. 12A):16.
54. BOWDEN CL, BUUGGEU AM, SWANN AC et al.: Efficacy of divalprocx rs. lithium and placebo in the treatment of mania. JAMA (1994) 271(12):918-924.
55. SHOPSIN Ii, GERSHON S, THOMPSON H, COLLINS P. Psychoactivc drugs in mania: a controlled comparison of lithium carbonate, chlorpromazinc, and haloperidol. Arch. Gen. KychiatiyWi?) 32(l):3-i-42. Historically important comparison of lithium remis antipsychotics in acute mania.
56. KECK PE, MCELKOY SL. STRAKO\VSKI S.M, IIALISTREKI TM. KIZERDL. WEST SA: Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder./ Clin. rsycl.niitiy(.l996) 57(4):147-151.
57. STERN MB: Contemporary approaches to the pharmacothcrapcutic management of Parkinson's disease: an overview. ,\ciiroh>gjf (1997) 49(Suppl. 1):S2-S9.
58. PARKINSON STUDY GROUP: Low-dose clozapinc for the treatment of drug-induced psychosis in Parkinson's disease. A'. Engl.J. Mccl. (1999) 340( 10):757-7o3.
59. WOLTERS EC, JANSEN ENH. TUYNMAN-QUA HG, BERGMANS PLM: Olanzapinc in the treatment of dopamincrgic psychosis in patients with Parkinson's disease. Aciiro/qtyCWo) 47(-i):1085-1087.
60. GRAHAM JM, SUSSMAN FD, FORD KS. SAGAR HI: Olanzapinc in the treatment of hallucinosis in idiopatliic Parkinson's disease: a cautionary note. J. Neurol. Neurosurg. Psychiatry (1998) 65(5):774-777.
61. FRIEDMAN J: Olanzapinc in the treatment of dopaminomimctic psychosis in patients with Parkinson's disease. At>Hrt>/u£v(1998) 5004):! 195-1196.
62. JIMENEZ-JIMENEZ FJ, TALLON-BARRANCO A, ORTI-PAREJA M. ZURDO M, PORTA J, MOLINA JA: Olanzapine can worsen parkinsonism. Neurology (1998)50(4):! 183-1184.
63. FRIEDMAN JH, GOLDSTEIN S, JACQUES C: Substituting clozapine for olanzapinc in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin. Xeuropbannacol. (1998) 21(5):285-288.
64. TRAN PV, DELLVA MA. TOLLEFSON GD, BEASLEY CM. JR., POTVIN JH, KIESLER CM: Extrapyramidal symptoms and tolcrability of olanzapinc versus haloperidol in the acute treatment of schizophrenia. J. din. Psychiatry (1997)58(5):205-211.
65. GHEUENS J, GREBB JA: Comments on article by Tran and associates, 'double-blind comparison of olanzapinc versus risperidone in treatment of schizophrenia and other psychotic disorders. J. Clin. Psycbü/ibaniiacol. (1998) 18(2):176-177.
66. TOLLEFSON GD, TRAN PV: Reply-letter to the editor. J Clin. Psychopharmacol. (1998) 18(2):177-179.
67. KINON BJ: The routine use of atypical antipsychotic agents: maintenance treatment. J Clin. Psychiatry(1998) 59(Suppl. 19):18-22.
68. CASEY DE: Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin. Psychiatry (1998) 59(SuppI. 3):31-37.
69. TOLLEFSON GD, BEASLEY CM Jr, TAMURA RN, TRAN PV, POTVIN JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskincsia with olanzapinc or halopcridol. Am. J. Phycbiatry (l991) 154(9):12-i8-1254. Documents a reduced risk of tardive dyskinesia with olanzapine than with typical antipsychotics.
70. SCHOOLEK NR. KANE JM: Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry (1982) 39(4):486-7.
71. HEASLEY CM. DELLVA MA. TAMUKA RN ct ah. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapinc or haloperidol. Br. J. Pychiatry(1199) 174(1):23-30.
72. BEASLEY CM, JR.. TOLLEFSON CD, TRAN PV: Safety of olanzapine./ Clin. Psycbifitiy(1997) 58(Suppl. 10):13-17.
73. WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: comparison of weight gain liabilities./ Clin. I'sycbuiliy(.l999) 60(6):358-363.
74. NEMEROFF CB: Dosing the antipsychotic medication olanzapine..J. Clin. I>sycbiatiy(l997)58(Supp\. 10H5-49.
75. GUI'TA S. DRONEY T, AL-SAMARRAI S, DELLER P, FRANK B: Olanzapine-induced weight gain. Aim. Clin. I'sycbi//TU998) 10(1)39.
76. SOLOMON CG, MANSON JE: Obesity and mortality: a review of the cpidemiologic data. Am. J. Clin. A'jifr. (1997) 66(Suppl.):1044S-1050S.
77. SONX'ERS JR: Obesity and cardiovascular disease. Clin. Cbcm. (1998) 44(8B):1821-1825.
78. FERTIG MK. BROOKS VG, SHELTON PS, ENGLISH C\V: Hyperglycemia associated with olanzapinc. J. Clin. Psychiatry (1998) 59(12):687;689.
79. WIRSHING DA, SPELLBERG BJ, ERHART S.M, MARDER SR. \VIRSHING \VC: Novel antipsychotics and new onset diabetes. liiol. I>sychiaty(.1998) 44(8):778-783.
80. CONNER P, FRIED G: Hyperprolactinemia; etiology, diagnosis and treatment alternatives. Actct Obstct. C-ynccul. Scfind. (1998) 77(3):249-262.
81. STAHL SM: Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials./ Clin. Psycbopbannacol. (1999) 60(Suppl. 10):31-41. Excellent review of atypical antipsychotic clinical pharmacology.
82. CRAWFORD AMK, BE/\SLEY CM JR., TOLLEFSON GD: The acute and long-term effect of olanzapinc compared with placebo and haloperidol on scrum prolactin concentrations. Scbtzopbr. Kcs. (1997) 26(l):41-54.
83. CANUSO CM, HANAU M, JHAMB KK, GREEN AI: Olanzapine use in women with antipsychotic-induccd hyperprolactincmia. Am. J. Psychiatry (1998) 155dO):1458.
84. DICKSON RA, DAWSON DT: Olanzapine and pregnancy. Can.]. Fsycbiatiy (1998) 43(2):196-197.
85. FLYNN S\V, ALTMAN S, MACEWAN G\V, BLACK LL, GREENIDGE LL, HONER \VG: Prolongation of clozapine-induced granulocytopenia associated with olanzapinc. .J. Clin. Psyclwpbarniacol. (1997) 17(6):-9W95.
86. BACHMANN S, SCHRÖDER J, PANTEL J et eil.: Olanzapine-induccd thrombocytopenia in association with idiopathic tliromlx>cytopcnic purpura. Br. J. Psychiatry (1998) 173):352.
87. PELONERO AL, LEVENSON JL, PANDURANGI AK: Ncurolcptic malignant syndrome: a review, Psycbialr. Sen: (1998) 49(9):1163-1172.
88. SACHDEV P, KRUK J. KNEEBONE M, KISSANE D: Clozapine-induccd neuroleptic malignant syndrome: review and report of new cases. J. Clin. Psycboiibannacol. (1995) 15(5):365-371.
89. FILICE GA, MCDOUGALL liC, ERCAN-FANG N, BILLINGTON CJ: Ncurolcptic malignant syndrome associated with olanzapinc. Ann. Pbannacolbr. (1998) 32(1 Dili 58-9.
90. MOLTZ DA, COEYTAUX KK: Case report: possible neuroleptic malignant syndrome associated with olanzapinc. J. Clin. sycbobarniacol. (1998) 18(6):-J85-486.
91. JOHNSON V, BRUXNER G: Neuroleptic malignant syndrome associated with olanzapine. Anst. A'Z J. Psychiatry (1998) 32(6):88-1-886.
92. BURKHARD PR, VINGERHOETS FJG: Olanzapinc-induccd neuroleptic malignant syndrome. Arch. Gen. Psychiatry dW)) 56(1):101-102.
93. MELTZER HY, COLA PA, PARSA M: Marked elevations of scrum crcatine kinasc activity associated with antipsychotic drug treatment. Neurvjisycbopbarmacology (1996) 1500:395-405.
94. MARCUS EL, VASS A, ZISLIN J: Marked elevation of serum creatine kinasc associated with olanzapine therapy. Ann. Pbannacotber. (1999) 33(6):697-700.
95. FOGEL F, DIAZ FE: Olanzapine overdose. Ann. Emerg. Meet. (199) 32(2):275-276.
96. STEPHENS BG. COLEMAN DE, BASELT RC: Olanzapinc-relatctI fatality. J. Forensic Sei. (1998) 43(6):1252-1253.
97. ELIAN AA: Fatal overdose of olanzapine. Foren. Sei. Int. (1998)9K3):231-235.
98. NIGHTENGALE I5S. CRUMLY JM LIAO J. LAWRENCE BJ, JACOBS EW: Economic outcomes of antipsychotic agents in a medicaitl population: traditional agents vs. risperidonc. Psycbo/ibiirmtfcol. Bull. (1998) 34(3):373-382.
99. REVICKI DA: Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-rclated studies. .J. Clin, fsycbiatry (1999) 60(SuppI. 1):7-11.
100. ROSENHECK R, CRAMER J, ALLAN E et dl.: Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch. Gen. I'sycblalry (1999)56(6)065-572.
101. PROCYSHYN RM. ZERJAV S: Drug utilization patterns and outcomes associated with in-hospital treatment with risperidonc or olanzapine. Clin. 'liier. (1998) 20(6):1203-1217.
102. GLAZER WM, JOHNSTONE UM: Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia./ Clin. iTC/>;V//ij(1997)85(Suppl. 10):50-54.
103. DAVIES A, LANGLEY PC, KEKS NA, CATTS SV, LAMBERTT, SCHWEITZER I: Kispcridone versus haloperidol: II. Cost-effectiveness. Clin. Tljer. (1998) 20(1):196-213.
104. BONDOLF1 G, DUFOUR H, I'ATRIS M et til.: Risperidonc versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am. J. I>sycbiatrya9)8) 155(4):499-504.